Sign up
Pharma Capital

Summit Therapeutics discovers new potential antibiotics for gonorrhoea

The drug discovery group is working to advance one of the antibiotics candidates to enter studies later this year
representing STDs
Summit noted that gonorrhoea is an area of high unmet medical need

Summit Therapeutics PLC (LON:SUMM) told investors that it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea at an industry event in Europe.

It was disclosed in a ‘late-breaking’ presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Madrid, Spain.

"Our strategy to tackle difficult to treat bacterial infections, such as gonorrhoea, is clear: to develop new mechanism antibiotics that are genuinely innovative treatment options with the potential to replace existing standards of care," said Dr David Roblin, Summit president of research and development.

READ: Summit Therapeutics boosted by new DMD drug analysis

He added: "We are encouraged by the profile of the series of gonorrhoea antibiotic candidates developed using our proprietary genetics-based discovery platform, and we look forward to selecting a preclinical candidate in the second half of this year."

Summit noted that gonorrhoea is an area of high unmet medical need with only one treatment option recommended by the US Centres for Disease Control, and, additionally, it is identified as a priority pathogen by the World Health Organisation.

The company highlighted that data presented at ECCMID showed a high potency against a range of gonorrhoea strains, including ones that were multi-drug resistant, high selectivity for gonorrhoea which minimises collateral damage to the microbiome.

Additionally, there was low potential for resistance development, and suitability for oral administration, it added.

Summit said it intends to select a candidate to enter studies in the second half of this year.

Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.